Back

Long-read Oxford Nanopore sequencing reveals complex rearrangements and regulatory disruption in malignant pleural mesothelioma

Alhazmi, M. H.; Poile, C.; Dzialo, J.; Bzura, A.; Kutywayo, K.; Fennell, D.; Hollox, E. J.

2026-06-02 oncology
10.64898/2026.05.26.26353864 medRxiv
Show abstract

Malignant pleural mesothelioma (MPM) is a rare malignancy characterised by extensive structural genomic alterations and a low burden of recurrent single nucleotide variants. However, the full spectrum and functional impact of structural variation (SVs) remain incompletely understood because short-read sequencing has limitation ability to resolve complex genomic rearrangements. Here, we performed integrated short-read and long-read whole-genome sequencing on tumour-normal pairs from three MPM patients, together with RNA sequencing and nanopore-derived promoter methylation profiling. Long-reads sequencing substantially improved SV detection, identifying 61-156 novel SVs per sample, including complex rearrangements and breakpoint-resolved events affecting cancer-associated genes. Complex SV clusters consistent with chromoplexy and chromothripsis were observed and frequently involved oncogenes. Integration with transcriptomics data showed that several SVs-affected genes, including WEE1 and GPC6, exhibited increased expression independent of gene dosage. Promoter methylation analysis revealed a conserved bimodal methylation landscape across tumours and a significant inverse relationship with gene expression. SV-associated genes showed coordinated promoter hypermethylation and transcriptional activation, suggesting that SVs may influence gene regulation through epigenetic mechanisms. Survival analysis using the TCGA-MESO cohort further showed that elevated expression of WEE1 and GPC6 was associated with poorer overall survival. Together, these findings highlight the value of long-read sequencing for uncovering functionally and clinically relevant structural variation in MPM.

Matching journals

The top 4 journals account for 50% of the predicted probability mass.

1
Nature Communications
4913 papers in training set
Top 0.5%
34.6%
2
Cancer Cell
38 papers in training set
Top 0.1%
7.1%
3
Clinical Cancer Research
58 papers in training set
Top 0.2%
6.7%
4
Acta Neuropathologica
51 papers in training set
Top 0.2%
5.1%
50% of probability mass above
5
Molecular Cancer
14 papers in training set
Top 0.2%
2.2%
6
Cancer Discovery
61 papers in training set
Top 0.9%
2.2%
7
Scientific Reports
3102 papers in training set
Top 51%
2.0%
8
eLife
5422 papers in training set
Top 37%
2.0%
9
Cell Genomics
162 papers in training set
Top 3%
1.8%
10
European Journal of Cancer
10 papers in training set
Top 0.2%
1.6%
11
The American Journal of Human Genetics
206 papers in training set
Top 2%
1.6%
12
Cell Reports
1338 papers in training set
Top 26%
1.6%
13
Cancer Research
116 papers in training set
Top 2%
1.4%
14
Proceedings of the National Academy of Sciences
2130 papers in training set
Top 37%
1.3%
15
Neuropathology and Applied Neurobiology
14 papers in training set
Top 0.3%
1.3%
16
iScience
1063 papers in training set
Top 23%
1.2%
17
JNCI: Journal of the National Cancer Institute
16 papers in training set
Top 0.5%
1.0%
18
Annals of Oncology
13 papers in training set
Top 0.7%
1.0%
19
Cell Reports Medicine
140 papers in training set
Top 6%
0.9%
20
Nature Genetics
240 papers in training set
Top 6%
0.9%
21
EMBO Molecular Medicine
85 papers in training set
Top 3%
0.9%
22
Acta Neuropathologica Communications
81 papers in training set
Top 1.0%
0.8%
23
npj Precision Oncology
48 papers in training set
Top 1%
0.8%
24
Communications Biology
886 papers in training set
Top 20%
0.8%
25
Science
429 papers in training set
Top 19%
0.8%
26
Molecular Oncology
50 papers in training set
Top 0.9%
0.8%
27
Leukemia
39 papers in training set
Top 0.7%
0.8%
28
Neuro-Oncology
30 papers in training set
Top 0.7%
0.8%
29
Frontiers in Oncology
95 papers in training set
Top 4%
0.5%
30
Journal of Hematology & Oncology
10 papers in training set
Top 0.3%
0.5%